BLTE offering history
Every offering-related filing in BELITE BIO, INC’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 202 filings back to Dec 1, 2021.
| Date | Filing | What it means | |
|---|---|---|---|
| Dec 2, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Dec 1, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Oct 22, 2025 | F-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Aug 8, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 7, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jan 27, 2025 | F-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Jan 27, 2025 | 424B7 → | UPDATE | Resale prospectus — existing holders registering to sell |
| Apr 29, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 16, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 1, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 30, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 30, 2023 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| May 22, 2023 | F-3 → | REGISTERED | F-3 registration — capacity to sell shares, not a sale yet |
| May 9, 2023 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| May 1, 2023 | F-3 → | REGISTERED | F-3 registration — capacity to sell shares, not a sale yet |
| Apr 29, 2022 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Apr 28, 2022 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Apr 28, 2022 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Apr 27, 2022 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Apr 25, 2022 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Apr 22, 2022 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Apr 20, 2022 | F-1/A → | REGISTERED | F-1/A registration — capacity to sell shares, not a sale yet |
| Apr 20, 2022 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Apr 5, 2022 | F-1 → | REGISTERED | F-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
BLTE offering FAQ
When did BLTE last execute an offering?
Per SEC filings, BELITE BIO, INC's most recent priced offering document is a 424B5 filed 2025-12-02. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did BLTE last announce or register an offering?
The most recent registration is a F-3ASR filed 2025-10-22. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.